Cramer's 'Mad Money' Recap: Ramblin' ROSE

"The Calpine worry is overdone," he said. Though it's definitely time to stop and buy Rosetta, "take your time and use limit orders," Cramer urged.

Biopower

On March 16, Cramer recommended Nastech Pharmaceutical (NSTK Quote), and since then the stock has moved up significantly, he told his viewers.

"I nailed Nastech because I know how biotech stocks work," Cramer said. "I believe I've got another Nastech, and the stock is Incyte (INCY Quote)."

Incyte, like Rosetta, is probably another stock investors have never heard of, Cramer said. But it's very similar to Nastech. With these stocks, people chase "the stuff dreams are made of," Cramer said.

These companies don't trade on nonexistent earnings; "they trade on hope," with the "sensible expectation" that someday they might develop a "promising" drug, he said.

When looking at stocks "that go on dreams," people should want two things, Cramer said. First, they should want a company that is developing drugs for several different markets, and second, the stocks must have "big end markets," he said.

Incyte doesn't have any drugs in phase III, but "it has potentially positive catalysts coming out soon," Cramer continued. He advised people to get into the stock before it releases its phase I and phase II data later on in the year.